Eisai Co., Ltd.
FY2025 Q3 Financial Results
Consolidated revenue for FY2025 Q3 was JPY 619.9 billion (up 103.1% YoY), operating income was JPY 54.5 billion (98.3% YoY), and net income attributable to owners of parent was JPY 41.8 billion (91.9% YoY).
Key Figures
- Consolidated Revenue: JPY 619.9 billion (103.1% YoY)
- Operating Income: JPY 54.5 billion (98.3% YoY)
- Net Income Attributable to Owners of Parent: JPY 41.8 billion (91.9% YoY)
AI要約
Summary of Financial Performance
Consolidated revenue for FY2025 Q3 was JPY 619.9 billion, an increase of 3.1% compared to the same period last year. Operating income was JPY 54.5 billion, a decrease of 1.7% YoY, while net income attributable to owners of parent was JPY 41.8 billion, down 8.1% YoY. The revenue growth was primarily driven by increased sales of the Alzheimer's treatment "Lecanemab," anticancer agent "Lenvima," and insomnia treatment "Duvieo." R&D expenses declined YoY due to a reassessment of development projects and cost efficiencies.
Segment Performance and Financial Position
The pharmaceutical business is divided into five regions: Japan, Americas, China, EMEA, and East Asia & Global South, recording a total revenue of JPY 610.1 billion, up 7.2% YoY. Particularly strong sales were seen in the Americas and China. On the financial position, total assets increased 7.2% from the previous fiscal year-end to JPY 1.4862 trillion, and total liabilities grew 9.6% to JPY 570.6 billion. No share buybacks were conducted, and the dividend is planned at JPY 160 per share.
